Oxford BioMedica plc Director's Share Purchase

RNS Number : 1846U

Oxford Biomedica PLC

14 October 2014

 

 

Oxford BioMedica plc Director's Share Purchase

Oxford, UK - 13 October 2014: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), a leading gene and cell therapy company, was informed that, on 13 October 2014, one of its Directors acquired ordinary shares of 1p each ("Ordinary Shares") as follows:

				Interest after purchase
Director / PDMR	Title	Price per share (p)	Number of Ordinary Shares acquired on 13 October 2014	Number of Ordinary Shares	% of total issued share capital
Paul Blake	Chief Development Officer	4.1p	243,902	2,311,999	0.09%

The issued share capital of the Company is 2,565,392,419 1p ordinary shares.

-Ends-

For further information, please contact:
Oxford BioMedica plc: John Dawson, Chief Executive Officer Tim Watts, Chief Financial Officer	Tel: [phone]
Media Enquiries: Mary-Jane Elliott/Emma Thompson/Matthew Neal/Laura Thornton Consilium Strategic Communications	Tel: [phone]

Notes for editors

About Oxford BioMedica^®

Oxford BioMedica plc (LSE: OXB) is a leading gene and cell therapy company with an unrivalled portfolio of gene therapy products in development and a platform of exclusive and pioneering technologies with which it designs, develops and manufactures unique gene-based medicines for some of world's largest pharmaceutical companies. Leveraging its proprietary LentiVector^® IP and gene delivery system technology platform and unique tumour antigen (5T4), Oxford BioMedica is advancing its pipeline of seven gene therapy products addressing diseases for which there are currently no treatments or that are inadequately treated today, including ocular and central nervous system disorders. OXB Solutions, the Company's industry-leading manufacturing and development business, provides services to collaborators and partners working in gene and cell therapy, including Novartis and Immune Design Corp.  In addition, the Company has licenced products and IP to Sanofi, Pfizer, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions and ImaginAb. Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.

 

END

 

 

RDSDGBDGLBBBGSX